Indianapolis Life Sciences: Inside the Ecosystem Reshaping US Pharma Services

A STATE REDEFINED BY PHARMA SERVICES

In 2024, Indiana made history. It overtook California to become the United States' number one exporting state for pharma services products, generating $27 billion in product exports and more than $99 billion in total economic activity. For a state more often associated with agriculture and motorsport, it was a statement of intent, and for those already operating within its pharma services ecosystem, it was long overdue recognition.

That achievement wasn't built overnight. Indiana has spent decades assembling the foundations: Eli Lilly and Company has been headquartered in Indianapolis since its founding in 1876; Roche Diagnostics established its North American headquarters in the city; Elanco Animal Health, one of the world's largest animal health companies, is based here; and Corteva Agriscience, the world's largest pure-play agricultural company, chose Indianapolis for its global headquarters. The pharmaceutical sector is the most concentrated subsector of Indiana's economy, with a location quotient of 2.83 compared to the national average. The Indianapolis metro area ranks fifth in the nation for its concentration in the pharmaceutical industry.

The gravitational pull of those anchor institutions has brought something more valuable still: a dense, interconnected ecosystem of CDMOs, CROs, emerging biotechs, research institutes, and specialist service providers that gives the region a genuine claim to being one of America's most capable pharma services environments outside the traditional coastal hubs.

‍

THE CDMO LANDSCAPE: FROM STERILE INJECTABLES TO GENE THERAPY

Contract Development and Manufacturing Organisations have become the backbone of modern drug commercialisation. As pharmaceutical and biotech companies, particularly smaller, innovation-driven firms, opt to outsource manufacturing rather than bear the capital intensity of building and maintaining their own facilities, CDMOs have moved from being logistical necessities to strategic partners. The global CDMO market, valued at around $246 billion in 2025, is projected to grow at a compound annual rate of roughly 9% through to 2035. North America holds a 38.5% share of that market, and the Midwest's domestic manufacturing credentials are increasingly attractive at a time when geopolitical risk and supply chain resilience are front of mind for biopharma leaders worldwide.

Indianapolis and its surrounding region have developed genuine depth across multiple CDMO specialisations.

‍

INCOG BioPharma Services

Few growth stories in the Indianapolis pharma services sector have been as striking as that of INCOG BioPharma Services. Founded in Fishers, Indiana in 2020, INCOG was built on a deliberately contrarian premise: that a CDMO could be both agile and uncompromising on quality, and that the industry had largely settled for less of both. That vision has been validated emphatically.

Specialising in sterile injectable biopharmaceuticals and fill/finish services for syringes, vials, and cartridges, INCOG completed a successful FDA inspection with zero observations in 2024, passed 20 customer audits from major biopharma firms in the same year, and expanded its team to 200 employees. It simultaneously broke ground on a second building, a 113,000-square-foot facility adjacent to its original campus, designed to support automated device assembly for autoinjectors, pens, wearable injectors, and syringe accessorising.

In December 2025, INCOG announced a further $200 million investment in its Fishers campus, with plans to grow to nearly 1,000 employees by 2030. When complete, the 21-acre site is expected to have capacity to produce up to 480 million units annually. It's a striking trajectory for a company that's barely five years old, and one that reflects both the strength of demand for high-quality sterile injectable manufacturing and the talent-driven culture INCOG has worked deliberately to build.

Vector Talent works directly with INCOG BioPharma and has witnessed first-hand the calibre of people and the pace of growth that has defined the company's rise. The hiring ambition INCOG has communicated publicly, with a specific focus on attracting top-tier talent in manufacturing, quality assurance, and client support, is matched by an internal culture that takes workforce quality as seriously as product quality.

‍

Genezen

While INCOG has established itself as a leader in fill/finish, Genezen represents another dimension of Indianapolis's CDMO capability. Founded in the city in 2014, Genezen is a specialist gene therapy CDMO with capabilities spanning AAV, lentiviral, retroviral, and other viral vector manufacturing modalities. The company partners with innovator organisations on cell and gene therapy programmes from concept through to commercial supply, with state-of-the-art facilities in Indianapolis and a second licensed site in Lexington, Massachusetts, carrying regulatory approvals from the FDA, EMA, Health Canada, and MFDS Korea.

The cell and gene therapy segment is projected to be the fastest-growing area of the broader CDMO market through to 2034. Genezen's decade-long investment in viral vector manufacturing capability positions Indianapolis as a credible address for companies in that space, which would have been a difficult argument to make ten years ago.

‍

CROS AND RESEARCH INFRASTRUCTURE

A CDMO ecosystem only functions fully when it's complemented by strong research and clinical infrastructure. Indianapolis has that in meaningful depth.

AIT Bioscience, based in Indianapolis, is a bioanalytical CRO supporting pre-clinical and clinical drug development and one of the first CROs globally to run regulated studies through an electronic lab notebook. Covance, now operating under the Labcorp Drug Development umbrella, has long maintained a central laboratory presence in Indiana. IQVIA, Syneos Health, BASi, and MiraVista Diagnostics are among the contracted research organisations operating within the state's ecosystem, providing services ranging from early-phase discovery work to late-stage clinical trial management and bioanalysis.

Underpinning all of this is Indiana University School of Medicine, the largest medical school in the United States by enrolment, and the Indiana Biosciences Research Institute (IBRI), a translational research organisation housed in the 16 Tech Innovation District in Indianapolis. IBRI was the nation's first industry-led collaborative pharma services research institute, and its positioning at the intersection of academia and industry has made it a significant incubator of clinical and scientific talent. Purdue University's William D. Young Institute for the Advanced Manufacturing of Pharmaceuticals adds further capacity for developing the kind of specialised workforce the sector urgently requires.

‍

BIOTECH: THE ANCHOR COMPANIES AND THE EMERGING CHALLENGERS

Any conversation about Indianapolis's pharma services ecosystem inevitably returns to Eli Lilly, and at this particular moment in the industry, for obvious reasons. Lilly's GLP-1 portfolio, anchored by Mounjaro and Zepbound (tirzepatide), has driven an extraordinary manufacturing expansion. The company committed $9 billion to its Lebanon, Indiana site within the LEAP Research and Innovation District for API production, in addition to a $1.2 billion investment to upgrade its Indianapolis Technology Centre. Since 2020, Lilly has committed more than $16 billion to new US and European manufacturing sites in total. Few investments in pharmaceutical manufacturing anywhere in the world have been at this scale.

What that scale of investment does, beyond the direct jobs it creates, is send a signal to the broader market. It draws suppliers, service providers, and talent to the region. It strengthens the case for a CDMO or CRO to establish or expand operations nearby. It validates Indianapolis as a serious address for pharmaceutical manufacturing and creates a secondary ecosystem of companies that service, supply, and support the anchor.

Novo Nordisk, Lilly's principal competitor in the GLP-1 market following the $16.5 billion acquisition of Catalent, operates a significant manufacturing presence in Bloomington, Indiana, with close to 100 roles recently posted in that location alone. Singota Solutions, also based in Bloomington, is an established CDMO offering aseptic filling, formulation development, and supply chain management, serving more than 200 clients across pharmaceutical, biotech, and animal health verticals. Baxter BioPharma Solutions, KP Pharmaceutical Technology, and Exelead round out a manufacturing cluster within the state that extends well beyond Indianapolis itself.

At the innovation end of the spectrum, the 16 Tech Innovation District is central to Indianapolis's strategy for building the next generation of the ecosystem. Home to IBRI, IU School of Medicine, and the Heartland BioWorks Tech Hub, which received $51 million in Economic Development Administration funding, the district is designed to move pharma services startups from early-stage research to commercial readiness. BioLaunch and BioTrain initiatives running within the district are building both company pipelines and the workforce to support them.

‍

THE TALENT EQUATION: INDIANAPOLIS'S STRUCTURAL ADVANTAGE

The defining challenge facing CDMOs, CROs, and biotech companies globally isn't capital, capacity, or regulatory complexity. It's talent. Pharma services occupations carry unemployment rates below 2%, and the sector's demand for highly specialised professionals consistently outpaces supply. A 2025 CBRE analysis found the median annual wage for medical scientists in the San Francisco Bay Area at over $145,000, and in the Boston-Cambridge market at approximately $129,000. In Indianapolis, the equivalent figure is $77,480.

That wage differential matters enormously for companies assessing where to build or scale operations. It doesn't mean Indianapolis talent is less qualified; it means a dollar invested in people goes further. For companies managing tight development budgets, or CDMOs working with narrow margins on contract manufacturing, the economics of the Midwest can be structurally significant.

Beyond cost, the region's talent infrastructure is developing rapidly. Indiana produced approximately 3,200 pharma services establishments employing more than 70,000 people statewide as of 2024. Indiana University School of Medicine, Purdue University, and the University of Notre Dame collectively generate a sustained pipeline of scientific, engineering, and technical graduates. BioCrossroads, Indiana's pharma services industry catalyst, has been formally designated the state's Industry Talent Association for the healthcare and pharma services sectors, adding coordination and pipeline development at scale.

The practical challenge, however, is that talent development takes time, and companies expanding at the pace of INCOG or the scale of Lilly's manufacturing buildout need experienced professionals now. For roles in quality assurance, regulatory affairs, process engineering, biomanufacturing, clinical operations, and scientific leadership, the competition for qualified candidates is genuinely acute. The ability to identify, attract, and convert the right person, particularly in a market where passive candidates rarely self-select, is increasingly what separates the companies that execute their growth plans from those that fall behind them.

‍

WHY INDIANAPOLIS DESERVES SERIOUS STRATEGIC ATTENTION

The coastal hubs of Boston and San Diego retain formidable advantages in early-stage biotech and R&D investment, and they likely will for some time. But the conversation in pharma services, covering manufacturing, clinical operations, and outsourced development, is shifting, and Indianapolis is increasingly well-positioned within that shift.

Geopolitical pressures and the strategic imperative for domestic manufacturing have given US-based CDMOs a tailwind that wasn't present five years ago. The BIOSECURE Act's scrutiny of Chinese contract manufacturers, with WuXi AppTec and WuXi Biologics having seen share prices fall 40-60% since 2022, has accelerated the search for domestic alternatives. Indiana's track record in pharma manufacturing, its logistics infrastructure, and its cost profile make it a credible destination for that redirected investment.

The Fishers Innovation District, 16 Tech, and the LEAP Research and Innovation District in Lebanon aren't marketing constructs. They represent real infrastructure investment designed to cluster research, manufacturing, logistics, and talent development in a geography that already has the scale and the pedigree to support it. When a company like INCOG BioPharma commits $200 million to a single campus expansion on a 21-acre site in Fishers, with a goal of 480 million units of annual capacity, that's not a bet on potential. It's a bet on what already exists.

‍

A MARKET THAT REWARDS SPECIALIST KNOWLEDGE

For hiring managers and business leaders within Indianapolis's pharma services sector, the competitive reality is this: the companies that will build and sustain market leadership in this environment are the ones that treat talent acquisition as a strategic function. The skills required across CDMOs, CROs, and biotech, from fill/finish manufacturing and analytical development to regulatory affairs and clinical project management, are scarce, specialist, and not easily transferable from adjacent sectors.

Vector Talent operates at the intersection of specialist sector knowledge and deep candidate networks across the pharma services industry. We understand the Indianapolis ecosystem, the companies operating within it, and the talent landscape that surrounds it, because we work with the organisations that are shaping it.